- A New Miniaturized PCR Instrument With SuperConvection(TM)
- At One Sixth the Price of QuanTyper(TM) Without Loss of Performance
- Next Generation of PCR Expected to Rapidly Penetrate the Market
UPPSALA, Sweden, Oct. 5 /CNW/ - AlphaHelix (Ticker: ALPH) has in a very short time developed a miniaturized PCR-instrument - AmpXpress(TM) - to meet demands for lower instrument prices. This was made possible through know-how obtained during the development of QuanTyper(TM). AmpXpress(TM) is substantially smaller in size and weight, silent, consumes less power and will attract customers that are looking for a fast, simple and easy to use PCR-instrument with SuperConvection(TM). AlphaHelix expects a rapid penetration of the market as the price of AmpXpress(TM) is comparable to low-end thermal cyclers (without a rotary format). The sales price of AmpXpress(TM) is only one sixth of the price of QuanTyper(TM) (the first version of AmpXpress(TM) is however a standard PCR instrument, and does not feature real-time detection (qPCR).
AmpXpress(TM) will be presented tomorrow at the BIOTECHNICA show in Hannover, Germany.
More information about AmpXpress(TM) is found at http://www.alphahelix.com. The product development has cost approximately 500 KSEK (gross). AlphaHelix has also been granted 250 KSEK by the Swedish Agency for Economic and Regional Growth. A first series of ten instruments has been initiated and patent applications have been submitted.
Technology assessment of SuperConvection and QuanTyper(TM) proceeds at the American biotechnology company and is not affected by the launch of AmpXpress(TM). Results from the evaluation are expected early November, at the earliest.
AlphaHelix Molecular Diagnostics AB (publ) develops instruments for rapid DNA analysis. The company's patented technology enables identification of virus and bacteria faster and with greater sensitivity than other technology available on the market. The AlphaHelix share is traded at AktieTorget http://www.aktietorget.se, which is a multilateral trading facility for small caps under the supervision of the Swedish Financial Supervisory Authority.
SOURCE ALPHAHELIX MOLECULAR DIAGNOSTICS AB
For further information: For further information: Lars Edvinsson, CEO, phone, +46-768-302-304; or Per Ersson, CFO, phone +46-708-66-24-45